Payer PolicyActive
SURG.00148 Spectral Analysis of Prostate Tissue by Fluorescence Spectroscopy
ANTHEM-SURG.00148
Anthem
Effective: April 16, 2025
Updated: December 30, 2025
Policy Summary
This policy addresses spectral analysis of prostate tissue using fluorescence spectroscopy (e.g., the ClariCore Biopsy System) for prostate evaluation/biopsy. Anthem considers this service investigational/experimental and not medically necessary; therefore, it is not covered for any indication. Coverage limitations: applies to all indications and settings, with no exceptions or covered circumstances.
Coverage Criteria Preview
Key requirements from the full policy
"Spectral analysis of prostate tissue by fluorescence spectroscopy is consideredinvestigational and not medically necessaryfor all indications."
Sign up to see full coverage criteria, indications, and limitations.